DOP2017000073A - Nuevos activadores de la guanilato ciclasa soluble y su uso - Google Patents
Nuevos activadores de la guanilato ciclasa soluble y su usoInfo
- Publication number
- DOP2017000073A DOP2017000073A DO2017000073A DO2017000073A DOP2017000073A DO P2017000073 A DOP2017000073 A DO P2017000073A DO 2017000073 A DO2017000073 A DO 2017000073A DO 2017000073 A DO2017000073 A DO 2017000073A DO P2017000073 A DOP2017000073 A DO P2017000073A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- soluble
- guanilate
- cycling
- new activators
- activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención se refiere a activadores de la guanilato ciclasa soluble y su uso en composiciones farmacéuticas, principalmente composiciones oftálmicas administradas por vía tópica. Las composiciones farmacéuticas son útiles para reducir la presión intraocular en los animales de las especies de mamíferos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052537P | 2014-09-19 | 2014-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000073A true DOP2017000073A (es) | 2017-04-16 |
Family
ID=54238488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000073A DOP2017000073A (es) | 2014-09-19 | 2017-03-16 | Nuevos activadores de la guanilato ciclasa soluble y su uso |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9938260B2 (es) |
| EP (1) | EP3194384A1 (es) |
| JP (3) | JP6678656B2 (es) |
| KR (1) | KR20170054508A (es) |
| CN (1) | CN106687456B (es) |
| AU (1) | AU2015319724B2 (es) |
| BR (1) | BR112017005660A2 (es) |
| CA (1) | CA2961745A1 (es) |
| CL (1) | CL2017000640A1 (es) |
| CO (1) | CO2017002506A2 (es) |
| CR (1) | CR20170102A (es) |
| DO (1) | DOP2017000073A (es) |
| EA (1) | EA033697B1 (es) |
| IL (1) | IL251094A0 (es) |
| MA (1) | MA40583A (es) |
| MX (1) | MX2017003621A (es) |
| PE (1) | PE20170937A1 (es) |
| PH (1) | PH12017500481A1 (es) |
| SG (1) | SG11201701915TA (es) |
| WO (1) | WO2016042536A1 (es) |
| ZA (1) | ZA201701835B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479029B2 (ja) | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| CR20170102A (es) * | 2014-09-19 | 2017-07-17 | Glaxosmithkline Ip Dev Ltd | Nuevos activadores de la guanilato ciclasa soluble y su uso |
| CU20170029A7 (es) | 2014-09-19 | 2017-08-08 | Bayer Pharma AG | Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| CN101553206B (zh) * | 2006-11-09 | 2012-11-21 | 爱尔康研究有限公司 | 用于药物递送的水不溶性聚合物基质 |
| AR069517A1 (es) | 2007-12-03 | 2010-01-27 | Smithkline Beecham Corp | Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| CN102414194A (zh) * | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| JP5636296B2 (ja) | 2011-01-20 | 2014-12-03 | 公益財団法人微生物化学研究会 | 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体 |
| CR20170102A (es) * | 2014-09-19 | 2017-07-17 | Glaxosmithkline Ip Dev Ltd | Nuevos activadores de la guanilato ciclasa soluble y su uso |
-
2015
- 2015-09-18 CR CR20170102A patent/CR20170102A/es unknown
- 2015-09-18 JP JP2017515074A patent/JP6678656B2/ja active Active
- 2015-09-18 KR KR1020177010181A patent/KR20170054508A/ko not_active Application Discontinuation
- 2015-09-18 BR BR112017005660A patent/BR112017005660A2/pt not_active Application Discontinuation
- 2015-09-18 WO PCT/IB2015/057219 patent/WO2016042536A1/en active Application Filing
- 2015-09-18 US US15/509,895 patent/US9938260B2/en active Active
- 2015-09-18 CA CA2961745A patent/CA2961745A1/en not_active Abandoned
- 2015-09-18 PE PE2017000478A patent/PE20170937A1/es unknown
- 2015-09-18 MX MX2017003621A patent/MX2017003621A/es unknown
- 2015-09-18 AU AU2015319724A patent/AU2015319724B2/en active Active
- 2015-09-18 SG SG11201701915TA patent/SG11201701915TA/en unknown
- 2015-09-18 EA EA201790655A patent/EA033697B1/ru not_active IP Right Cessation
- 2015-09-18 CN CN201580050717.XA patent/CN106687456B/zh active Active
- 2015-09-18 MA MA040583A patent/MA40583A/fr unknown
- 2015-09-18 EP EP15772026.9A patent/EP3194384A1/en not_active Withdrawn
-
2017
- 2017-03-12 IL IL251094A patent/IL251094A0/en unknown
- 2017-03-14 PH PH12017500481A patent/PH12017500481A1/en unknown
- 2017-03-14 ZA ZA2017/01835A patent/ZA201701835B/en unknown
- 2017-03-16 CO CONC2017/0002506A patent/CO2017002506A2/es unknown
- 2017-03-16 CL CL2017000640A patent/CL2017000640A1/es unknown
- 2017-03-16 DO DO2017000073A patent/DOP2017000073A/es unknown
-
2018
- 2018-03-05 US US15/911,797 patent/US10472350B2/en active Active
-
2020
- 2020-03-02 JP JP2020035272A patent/JP6908747B2/ja active Active
-
2021
- 2021-06-30 JP JP2021109106A patent/JP2021155450A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2017002506A2 (es) | 2017-07-28 |
| JP6908747B2 (ja) | 2021-07-28 |
| CN106687456A (zh) | 2017-05-17 |
| ZA201701835B (en) | 2018-12-19 |
| CR20170102A (es) | 2017-07-17 |
| CN106687456B (zh) | 2019-12-03 |
| US10472350B2 (en) | 2019-11-12 |
| PH12017500481A1 (en) | 2017-08-07 |
| EA201790655A1 (ru) | 2017-08-31 |
| WO2016042536A1 (en) | 2016-03-24 |
| BR112017005660A2 (pt) | 2017-12-19 |
| AU2015319724B2 (en) | 2018-05-10 |
| MA40583A (fr) | 2016-03-24 |
| PE20170937A1 (es) | 2017-07-13 |
| US20180194756A1 (en) | 2018-07-12 |
| JP2020105189A (ja) | 2020-07-09 |
| JP2021155450A (ja) | 2021-10-07 |
| IL251094A0 (en) | 2017-04-30 |
| US9938260B2 (en) | 2018-04-10 |
| CL2017000640A1 (es) | 2017-10-06 |
| US20170305888A1 (en) | 2017-10-26 |
| JP2017527602A (ja) | 2017-09-21 |
| EA033697B1 (ru) | 2019-11-18 |
| SG11201701915TA (en) | 2017-04-27 |
| CA2961745A1 (en) | 2016-03-24 |
| MX2017003621A (es) | 2017-07-14 |
| JP6678656B2 (ja) | 2020-04-08 |
| AU2015319724A1 (en) | 2017-04-06 |
| EP3194384A1 (en) | 2017-07-26 |
| KR20170054508A (ko) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000073A (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| ECSP17078433A (es) | Composiciones de ácido obeticólico y métodos de uso | |
| NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| CO2017002963A2 (es) | Espiro-tiazolonas | |
| UY35665A (es) | ?compuestos de carboxamida, proceso de preparación y su uso como nematicidas?. | |
| UY36958A (es) | Compuestos para administración intracelular | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| CR20180110A (es) | Libobactina para uso en el tratamiento de la mastitis bovina | |
| GT201500116A (es) | Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo |